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Abstract
αβ and γδ lineage T cells are thought to arise from a common CD4−CD8− progenitor in the
thymus. However, the molecular pathways controlling fate selection and maturation of these two
lineages remain poorly understood. We have demonstrated recently that a ubiquitously expressed
ribosomal protein, Rpl22, is selectively required for the development of αβ lineage T cells.
Germline ablation of Rpl22 impairs development of αβ lineage, but not γδ lineage, T cells through
activation of a p53-dependent checkpoint. In this study, we investigate the downstream effectors
employed by p53 to impair T cell development. We found that many p53 targets were induced in
Rpl22−/− thymocytes, including miR-34a, PUMA, p21waf, Bax, and Noxa. Notably, the pro-
apoptotic factor Bim, while not a direct p53 target, was also strongly induced in Rpl22−/− T cells.
Gain-of-function analysis indicated that overexpression of miR-34a caused a developmental arrest
reminiscent of that induced by p53 in Rpl22-deficient T cells; however, only a few p53 targets,
when individually ablated by gene targeting or knockdown, alleviated developmental arrest. Co-
elimination of PUMA and Bim resulted in a nearly complete restoration of development of
Rpl22−/− thymocytes, indicating that p53-mediated arrest is enforced principally through effects
on cell survival. Surprisingly, co-elimination of the primary p53 regulators of cell cycle arrest
(p21waf) and apoptosis (PUMA) actually abrogated the partial rescue caused by loss of PUMA
alone, suggesting that the G1 checkpoint protein p21waf might actually facilitate thymocyte
development in some contexts.
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Introduction
Development of αβ-lineage T cell progenitors from the CD4−CD8− double negative (DN)3
stage to the CD4+CD8+ double positive (DP) stage requires traversal of the β-selection
checkpoint, which ensures that only progenitors that have productively rearranged the T cell
receptor (TCR) β locus will survive. DN thymocytes can be further subdivided based upon
the surface expression of CD25 and CD44 into four subsets: DN1, CD44+CD25−; DN2,
CD44+CD25+; DN3, CD44−CD25+; and DN4, CD44−CD25−. TCRβ rearrangement is
initiated as thymocytes develop from the DN2 to the DN3 stage. If during this transition
rearrangement of the TCRβ locus fails to preserve the translational reading frame of TCRβ,
the cells die by apoptosis (1); however, if the translational reading frame is preserved and
produces a functional TCRβ protein, it assembles with the remaining subunits of the pre-T
cell receptor (pre-TCR) complex (pre-Tα, along with CD3γ, δ, ε, and ζ) and transduces
ligand-independent signals, resulting in a number of developmental outcomes including
termination of TCRβ rearrangement (i.e., allelic exclusion), rescue from cell death,
proliferation, and differentiation to the DP stage (2, 3). The pre-TCR complex orchestrates
these developmental outcomes by regulating the expression or function of numerous
transcription factors including early growth response genes (Egr1–3) and NF-ATc, which
cooperatively yield increased expression of inhibitor of DNA binding 3 (ID3) and traversal
of the β-checkpoint (4–6).
We recently made the surprising finding that the ribosomal protein L22 (Rpl22) is required
for traversal of the β-selection checkpoint and so also appears to be an important molecular
effector of the developmental outcomes orchestrated by pre-TCR signaling (7). Rpl22 is a
ubiquitously expressed RNA binding protein that is a component of the 60S ribosomal
subunit but is not essential for global or CAP-dependent translation (8, 9). Strikingly, Rpl22
ablation does not affect health or size of the mice yet does result in a profound T
lymphopenia, with most αβ lineage T cells arresting at the β-selection checkpoint at the DN3
stage (7). The developmental arrest at the DN3 stage in Rpl22-deficient mice results from an
αβ lineage-restricted induction of the p53 tumor suppressor, as epistasis analysis reveals that
the developmental arrest is completely alleviated by eliminating p53 through gene ablation
(7). Interestingly, p53 induction in Rpl22-deficient DN3 cells appears to result from
increased translation, implicating Rpl22 as a regulator of p53 synthesis. Other ribosomal
protein defects have been implicated in impairing hematopoietic cell development (e.g.,
RpS19 mutations disrupting erythroid development in Diamond-Blackfan Anemia) (10);
however, no ribosomal protein mutations had previously been shown to selectively impair T
cell development (11).
While ribosomal proteins are critical components of cellular ribosomes on which all proteins
are synthesized, an increasing number of reports have revealed additional roles for
ribosomal proteins in regulating fundamental cellular processes, such as survival, from
outside of the ribosome (12). Among these extraribosomal functions is the regulation of p53
expression. For example, ribosomal protein S7 that fails to be incorporated into ribosomes
because of impaired small ribosomal subunit assembly, enhances the translation of the
ribosomal protein L11 (Rpl11), which in turn, activates p53 by preventing its degradation by
the ubiquitin ligase MDM2 (13). Likewise, ribosomal proteins Rpl5 and Rpl23 are also able
to activate p53 by binding to and impairing MDM2 function upon being released from the
nucleolus under conditions of nucleolar stress (14, 15). Finally, Rpl26 is able to directly
increase the rate of p53 synthesis via binding to the 5′ untranslated region (UTR) of p53
3Abbreviations: DN, double negative; DP, double positive; TCR, T cell receptor, pre-TCR, pre-T cell receptor; RpL22, ribosomal
protein L22; BH3, Bcl-2-homology domain 3-only; Bax, Bcl-associated-X protein; Noxa, NADPH oxidase activator 1; PUMA, p53-
upregulated modulator of apoptosis
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mRNA (16, 17). Therefore, while some ribosomal proteins control p53 by regulating its
stability, other ribosomal proteins (Rpl26 and Rpl22) do so by altering p53 translation (7,
13).
The tumor suppressor p53 regulates a complex and multi-layered network of pro-apoptotic
and cell cycle inhibitory factors and mediates life or death decisions in response to stresses.
One way in which p53 activation regulates survival is through the transcriptional induction
of pro-apoptotic Bcl-2-homology domain 3-only (BH3) family of proteins (18). This family
of proteins includes Bcl-associated X protein (Bax), NADPH oxidase activator 1 (Noxa),
and p53-upregulated modulator of apoptosis (PUMA). An additional BH3-only family
member, Bim, that is not a direct p53 target, is nevertheless induced in T cells in response to
stresses such as cytokine withdrawal and DNA damage and ultimately leads to compromised
mitochondrial integrity and apoptosis (19, 20). Several of these proteins have been identified
as critical effectors of p53-mediated apoptosis or growth arrest. PUMA-deficient T cells are
highly resistant to UV and chemical-induced apoptosis, despite large increases in p53
protein (21). Similarly, Bim or Noxa-deficient T cell precursors or MEF cells exhibited
enhanced resistance to cell death in response to similar stimuli (19, 22, 23). In addition to its
role in regulating cell survival, p53 can also control cell-cycle progression via the G1
checkpoint protein p21waf, which allows for reversible cell cycle arrest in the event of DNA
damage (24–26) or for a permanent arrest through activation of an oncogene-induced
senescence program. In addition to the transactivation of particular downstream regulators
of growth or survival, p53 can also induce the micro-RNA miR-34a, which is able to
regulate a large battery of individual p53 effectors and is thereby able to replicate many of
the consequences of p53 induction, including G1 arrest and apoptotic cell death (27).
Many downstream targets are induced upon p53 activation, but the particular effectors
responsible for the diverse developmental outcomes differ depending on the stimulus
responsible for p53 induction. For example, PUMA orchestrates thymocyte death in
response to DNA damage, whereas Noxa is more important in the context of oncogene
activation (28). While our observations indicated a link between Rpl22 and p53 protein
expression in developing αβ lineage T cells, the p53 targets responsible for the arrest of
thymocyte development were unknown. Herein we identify the targets upregulated
following p53 activation in Rpl22-deficient αβ-lineage precursors and then assess their role
in the resulting p53-mediated developmental block. We found that many direct targets of
p53 activation were induced, including miR-34a, PUMA, p21waf, Bax, and Noxa, as well as
the pro-apoptotic BH3 only gene Bim, which is not considered to be a direct p53 target.
Interestingly, while gain-of-function analysis indicated that overexpression of miR-34a is
sufficient to impair development in a similar fashion to that observed following p53
induction in Rpl22-deficient T cells, few pro-apoptotic factors (PUMA and Bim) exerted
sufficiently potent effects such that development was detectably rescued by their individual
elimination. Importantly, co-elimination of the pro-apoptotic factors, PUMA and Bim,
resulted in a nearly complete rescue of the development of Rpl22−/− thymocytes. In contrast,
simultaneous elimination of the primary p53 regulators of cell cycle arrest (p21waf) and
apoptosis (PUMA) actually afforded less rescue in terms of cell frequency and cellularity
than ablation of PUMA alone, suggesting that loss of the G1 checkpoint protein p21waf
renders thymocytes more sensitive to arrest by other p53 effectors.
Materials and Methods
Mice
All mouse strains were housed in the Association for Assessment and Accreditation of
Laboratory Animal Care-accredited Laboratory Animal Facility at Fox Chase and were
handled in accordance with Institutional Animal Care and Use Committee approved
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protocols. The following mouse strains were used: Rpl22-deficient (7); PUMA-deficient
(21); Rag2-deficient (29); p21waf-deficient (Jackson Research Laboratories, Bar Harbor,
ME)(24); pre-Tα-deficient (A generous gift of Dr. H von Boehmer, Dana Farber Cancer
Institute)(30); and p53-deficient (A generous gift of Dr. Maureen Murphy, Fox Chase
Cancer Center)(31). Genotypes were confirmed performing PCR analysis on tail DNA at
weaning and again prior to use in experiments.
Quantitative real-time PCR
Total RNA was isolated from primary cells using the RNA-Easy system (Qiagen, Valencia,
Ca). Purified mRNA was converted to cDNA using Superscript II reverse transcription PCR
with oligo dT(12–18) primers (Invitrogen, Carlsbad, CA). Quantitative real-time PCR was
performed on the Prism 7700 thermocycler (Applied Biosystems, Carlsbad, CA) using
Taqman Real-time PCR primer/probe sets specific to murine PUMA/Bbc3
(Mm00519268_m1), Noxa/Pmaip1 (Mm00451763_m1), and Bim/(Bcl2l-11)
(Mm01333921_m1). P21waf/Cdkn1a and Bax primer/probe sets were custom generated by
the Fox Chase Cancer Center Genomics Core Facility. miR RNA was isolated using the miR
Easy system in conjunction with the RNeasy MinElute Cleanup Kit (Qiagen, Valencia, CA).
Isolated RNA was converted to cDNA by the Multiscribe RT-PCR kit (Applied
Biosystems). miR expression was determined by the Taqman Micro RNA assay for miR-34a
and sno-202. Real-time PCR was performed as indicated above.
Anti-CD3 treatment
Mice were injected intraperitoneally with affinity column purified anti-CD3 (145-2C11) at
10µg/g body weight in a total volume of 200µL of PBS per mouse or were injected with
PBS alone. Mice were then harvested at the indicated times. For each experiment, 4 mice
received PBS (control) treatment and 2 mice/time point received anti-CD3 injection.
CD4−CD8−CD44− (DN3+DN4) thymocytes were isolated by cell sorting and used to
generate cDNA for real-time PCR analysis or to produce detergent extracts for
immunoblotting.
Immunoblot analysis
Cells were lysed in NP-40 Lysis Buffer (1% NP-40, 50mM TRIS pH 8.0, 150mM NaCl)
with a complete mini-tab inhibitor tablet. Samples were resolved on NuPage Novex Bis-Tris
gels (Invitrogen) and blotted with the following antibodies: anti-p53 (Clone #IMX25, Leica
Microsystems, UK), anti-Bim/BOD (Clone AAP-330, Assay Designs Inc., Ann Arbor, MI),
anti-Noxa (FL-103, Santa Cruz Bio., CA), anti-myc tag (EQKLISEEDL) and anti-Bax (Cell
Signaling Technologies, Beverly, MA).
OP9 cell cultures and shRNA retroviral transduction
Viral particles were produced by transient calcium-phosphate transfection of Phoenix cells
with shRNAs expressed in the MSCV-based vectors, LMP or LMS, as described (32). Fetal
livers were harvested on day 14 of gestation and genotyped as described above.
Hematopoietic precursors were expanded on OP9-DL1 expressing monolayers containing
IL7 (5ng/mL) and Flt-3 (5ng/mL). After four days, cells were spin-infected with retrovirus
containing shRNA targeting Bax (MLS-Bax), Bim (MLS-Bim), Noxa (MLS-Noxa), or an
irrelevant control (MLS-T-1052). For p53 knockdown, precursors were infected with a
control vector (LMP) or LMP-p53 (provided by S. Lowe, Cold Spring Harbor Laboratory).
Cells were cultured for the indicated times and analyzed by flow cytometry.
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Flow cytometric analysis
Single cell suspensions of thymic cells were stained with antibodies to CD4 (clone GK1.5),
CD25 (clone 7D4), CD44 (clone IM7), γδTCR (clone GL3), and CD8 (Clone 53-6.7)
(BioLegend, San Diego, CA). For cell death assays, cells were stained with Annexin-V PE
(BD Biosciences, San Jose, CA). Data were collected using the LSRII (BD Biosciences, San
Jose, CA) and were analyzed using FlowJo software (Tree Star, Ashland, OR).
Myc-tagged Noxa construct
Two consecutive Myc-Tag sequences encoding EQKLISEEDL were appended to the 5´ end
of the Noxa mRNA sequence, along with the relevant 3´ UTR binding region for the Noxa
shRNA. The PCR-generated product was directionally cloned into PMIY dsCherry II and
then used to generate virus for stable retroviral transduction into Scid.adh cells. Cells
transduced with either control shRNA or Noxa shRNA were sorted for GFP expression and
used in Immunoblot analysis for Myc-tag expression (anti-Myc Tag (71D10), Cell Signaling
Technologies, MA).
Cell cycle analysis
Cell cycle analysis was performed using the FITC BrdU Flow Kit (BD Pharmingen, San
Jose, CA). Briefly, mice were injected intraperitoneally with 1mg/mL of BrdU in sterile
PBS and rested for 4 h prior to harvesting. Thymocytes were surface stained with T cell
markers then fixed and permeabilized with BD Cytofix/Cytoperm buffer. Each sample was
treated with 30µg DNAse for 1 h prior to intracellular staining with anti-BrdU FITC and 7-
amino-actinomycin D (7-AAD) and analysis on the LSR II.
Results
Trp53 ablation restores development of RpL22-deficient αβ-lineage T cells
Germline ablation of the Rpl22 gene in mice results in a severe T lymphopenia caused by
selective impairment of αβ-lineage T cell development in the thymus, with few T cell
precursors maturing beyond the CD4−CD8− DN stage (Figure 1A). Further subsetting of
DN thymocytes based on differential expression of CD44 and CD25, revealed that the
developmental block occurs at the CD44−CD25+ DN3 stage (Figure 1B). The impairment in
T cell development in Rpl22−/− mice was associated with increased apoptosis, as indicated
by elevated Annexin V binding in the majority of T cell subsets (Figure 1C). Interestingly,
the developmental blockade was preferentially manifested in αβ lineage precursors, as
development of γδ lineage cells was only mildly impaired (Figure 1B). Previous analysis
had revealed that the development of Rpl22-deficient thymocytes is impaired by activation
of a p53-dependent checkpoint (7). Indeed, development of Rpl22-deficient thymocytes is
completely restored by p53 deficiency, as illustrated by the total and complete rescue of T
cell development in Rpl22−/−Trp53−/− mice. These mice demonstrated both restored thymic
cellularity and representation of T cell populations (Figure 1A and B) as well as reduced
apoptosis (Figure 1C).
The developmental arrest of T cell development in Rpl22−/− mice is associated with the
induction of multiple p53 effectors
The relative resistance of developing γδ lineage cells to Rpl22-deficiency results from the
absence of p53 induction in these cells (7). Accordingly, we compared the expression of p53
effector molecules in αβ and γδ lineage precursors to gain insight into those responsible for
the observed developmental block. We performed quantitative real-time PCR analysis on
sorted αβ-lineage DN3 and γδ T cells from Rpl22+/+ and Rpl22−/− mice as well as from pre-
Tα-deficient (Ptcra−/−) mice, which are similarly arrested at the DN3 stage, albeit by a
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distinct mechanism (33, 34). We observed a 2 to 6-fold increase in both cell cycle arrest and
pro-apoptotic factors in Rpl22−/− αβ-lineage thymocytes, including p21waf, Bax, Bim, and
PUMA, and a consistently robust increase in Noxa (Figure 2). The increased expression of
p21waf and the pro-apoptotic factors was restricted to Rpl22−/− αβ-lineage cells, as it was
not observed in either Rpl22−/− γδ lineage cells or in Ptcra−/− mice, where the
developmental arrest results from the absence of pre-TCR signaling (30). Finally, we did
observe Noxa induction in Rpl22−/− γδ lineage cells, but to a much lesser extent than in
Rpl22−/− αβ lineage DN3 cells (Figure 2). Taken together, these data suggest that the
impairment in αβ lineage T cell development in Rpl22-deficient mice is correlated with
induction of numerous direct and indirect p53 targets capable of inducing cell cycle arrest
(p21waf) and apoptosis (Bax, Noxa, PUMA, and Bim).
Developing T lineage precursors that undergo apoptosis in the thymus are rapidly cleared by
phagocytosis (35). Accordingly, it is possible that the expression analysis in Figure 2 could
have been affected by the relative efficiency with which different populations are
phagocytically removed. In an attempt to mitigate this concern, we employed a model
system in which the traversal of the β-selection checkpoint could be induced in a
synchronous fashion, using anti-CD3 stimulation of pre-TCR deficient (Rag2-deficient)
thymocytes (36). Rag2-deficient thymocytes that were either Rpl22+/+ or Rpl22−/− were
stimulated in vivo by intraperitoneal injection with anti-CD3 antibody, which mimics a pre-
TCR stimulus and induces thymocytes to mature from the DN3 to the CD44−CD25− DN4
stage within 24 h (36) (Figure 3A). We observed that by 24 h after stimulation, the extent of
CD25 down modulation was beginning to lag in the Rpl22−/− mice, even though both
Rpl22+/+ and Rpl22−/− thymocyte populations had received equivalent stimulation, as
shown by identical induction of CD5, an indicator of signal intensity (37) (Figure 3A).
Rpl22−/− thymocytes exhibited elevated levels of p53 protein even before anti-CD3
stimulation that were robustly induced upon anti-CD3 treatment (Figure 3B). Taken
together, these data indicate that the induction of p53 began to manifest as a developmental
arrest by 24 h post stimulation (Figure 3A,B). Surprisingly, we also observed a modest
induction of p53 in anti-CD3 stimulated Rpl22+/+ thymocytes (Figure 3B); moreover, it was
transient, as it abated by 48 h in Rpl22+/+ but not Rpl22−/− thymocytes, where its sustained
expression leads to cell death (Figure 3B). The cause of p53 induction in anti-CD3
stimulated Rpl22+/+ thymocytes is not clear, but could be due to a transient stress response
associated with the extensive proliferation caused by this mitogenic signal. Having
identified an early stage in the p53-mediated developmental block of Rpl22−/− thymocytes
(24 h), we performed quantitative real-time PCR analysis to determine whether the set of
p53 effectors induced under these conditions was similar to those above. Indeed, as in
asynchronously developing Rpl22−/− thymocyte populations, we found 2 to 6-fold increases
in expression of the pro-apoptotic factors PUMA, Bax, and Noxa as compared to PBS
treated Rpl22+/+ cells (Figure 3C). In contrast to what we observed in asynchronously
developing Rpl22−/− thymocytes (Figure 2), expression of p21waf1 and Bim decreased in
both the anti-CD3 stimulated Rpl22+/+ and Rpl22−/− cells (Figure 3C). Currently, the basis
for this difference in p21waf and Bim expression between mitogenically stimulated and
asynchronously developing Rpl22−/− thymocytes is unknown, however this may reflect a
temporal delay in induction relative to that of other p53 targets.
Expression of miR-34a arrests thymocyte development
miRs are small noncoding RNAs that can regulate gene expression by altering mRNA
stability or translation (27, 38, 39). miR-34a was recently identified as a direct p53 target,
whose induction is capable of independently replicating many of the effects of p53
activation, including G1 arrest and apoptosis (27). Therefore, we asked if miR-34a were
induced by p53 in RpL22-deficient thymocytes. Indeed, both control Rag2−/−Rpl22−/− cells
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and those stimulated to differentiate with anti-CD3 exhibited a 2-fold increase in miR-34a
expression over control treated RpL22-sufficient T cells (Figure 4A). Since miR-34a is
induced in Rpl22-deficient T cells, we asked if miR-34a expression alone was sufficient to
replicate the effects of p53 induction and arrest T cell development. To address this
question, we used a gain-of-function approach by retrovirally transducing miR-34a into
adult DN thymocytes and monitoring development in OP9-DL1 stromal cell cultures. OP9-
DL1 cells support the development of immature T cells up through the DP stage in vitro
(40). Cells transduced with empty vector or mutant miR-34a (MIR34M) displayed a marked
increase in the number of T lineage precursors that had developed to the immature DP stage
between days 1 and 4 (Figure 4B). Conversely, transduction with miR-34a significantly
impaired development to the DP stage, both regarding the frequency and number of cells
(Figure 4B, C). Our findings suggest that induction of the p53 target miR-34a plays an
important role in the p53-mediated blockade of T cell development in Rpl22−/− mice.
Ablation of the Cdkn1a gene encoding p21waf fails to alleviate the developmental blockade
of RpL22-deficient αβ T cells
Since gain-of-function analysis revealed that enforced expression of miR-34a caused a
developmental arrest reminiscent to that resulting from p53 activation in Rpl22−/−
thymocytes, we asked if loss-of-function analysis would reveal which of the induced p53
effectors might play a sufficiently important role that their individual ablation alleviates the
developmental block. p53 activation induces targets that fall into two broad functional
classes: those that regulate cell growth and those that regulate survival. Among these factors,
the most frequently implicated in regulating cell growth and survival are p21waf and PUMA,
respectively (21, 24, 41). Because both of these p53 targets are induced in Rpl22−/−
thymocytes (Figures 2 and 3C), we employed loss-of-function analysis to investigate their
importance in the p53-mediated impairment of thymocyte development. Specifically, we
assessed whether p21waf-deficiency (i.e., Cdkn1a ablation) would alleviate the development
block and restore development of Rpl22−/− thymocytes to the DP stage. Surprisingly,
rendering Rpl22-deficient thymocytes deficient for p21waf (Rpl22−/−Cdkn1a−/−) failed to
alleviate the developmental arrest, as the vast majority of thymocytes remained at the DN
stage, primarily at the β-selection checkpoint at DN3, just as in p21waf-expressing Rpl22−/−
mice (Figure 5A,B). Moreover, p21waf-deficiency did not suppress the increased apoptosis
routinely observed in Rpl22-deficient thymocytes (Figure 5C). These data indicate that
elimination of p21waf alone was not sufficient to restore development of Rpl22−/−
thymocytes, perhaps because pro-apoptotic p53 targets were still present and might be
inducing cell death.
PUMA-deficiency suppresses p53-mediated apoptosis and partially restores development
of RpL22-deficient thymocytes
Since ablation of the cell cycle regulator p21waf failed to rescue development, we attempted
to rescue the p53-mediated developmental arrest by disabling apoptotic pathways. PUMA is
a pro-apoptotic BH3 family member and a major p53-activated inducer of apoptosis, whose
ablation can abrogate p53-mediated death induced by cellular insults/stressors, including γ-
irradiation, dexamethasone, or cytokine withdrawal (21). We therefore asked whether
PUMA-deficiency would alleviate the p53-induced developmental block of Rpl22−/−
thymocytes. Indeed, relative to mice singly deficient for Rpl22, those doubly-deficient for
both PUMA and Rpl22 exhibited a significant increase in both the frequency and absolute
number of thymocytes that developed to the DP stage (Figure 6A). Nevertheless, this
represented only a partial rescue, returning thymic cellularity to only approximately 10% of
wild type levels (Figure 6A) and failing to cause a significant increase in the absolute
number of cells that have developed beyond the DN3 stage to DN4 stage cells (Figure 6B).
Finally, an examination of cell viability by Annexin V staining indicated that while PUMA
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deletion substantially reduced the level of apoptosis in nearly all T cell subsets, it appeared
that the suppression of apoptosis was incomplete, as indicated by the elevated apoptosis
manifested in total Rpl22−/−Puma−/− thymocytes and the CD4 SP thymocyte subsets,
relative to littermate controls (Figure 6C). Taken together, these data indicate that PUMA
plays an important role in the p53-mediated promotion of apoptosis in Rpl22−/− thymocytes;
however, unlike thymocyte apoptosis following γ-irradiation which is fully rescued by
PUMA deficiency (21), the apoptosis accompanying Rpl22-deficiency appears to involve
additional pro-apoptotic effectors.
To determine whether pro-apoptotic effectors other than PUMA were contributing to the
death of Rpl22−/− thymocytes, we investigated the other death effectors identified in our
expression analysis (Bax, Bim, and Noxa; Figure 2). Their role in the developmental block
of Rpl22−/− thymocytes was examined by knocking down their expression in Rpl22−/− fetal
progenitors and monitoring the effect on development on OP9-DL1 monolayers as was done
for adult progenitors in Figure 4. Analysis was restricted to GFP+ cells that had been
transduced with the shRNA retroviral vector (MLS)(32). A comparison of GFP+ cells
reaching the DP stage in shRNA-treated versus the control shRNA-expressing cells reveals
the extent to which knockdown of the the death effectors blunts p53-mediated apoptosis and
alleviates the developmental blockade of αβ lineage Rpl22−/− thymocytes (Figure 7).
Knockdown of p53 in Rpl22−/− progenitors restored development to about half the level
observed in control-transduced Rpl22+/+ progenitors and was used to normalize results from
knockdown of pro-apoptotic effectors (Figure 7A). Surprisingly, while expression of
multiple pro-apoptotic effectors was induced in Rpl22−/− thymocytes (Bim, Noxa, and Bax),
knocking down the expression of Noxa and Bax failed to alleviate the developmental
blockade and promote development to the DP stage (Figure 7A and C); however,
knockdown of Bim did result in a partial rescue of development, restoring development
approximately half as effectively as did knocking down p53 (Figure 7A). Importantly, when
Bim was knocked down in Rpl22−/−Puma−/− T cells, the rescue of development to the DP
stage was nearly equivalent to that resulting from knocking down p53 itself (defined as
100%: Figure 7B and C). In summary, our loss-of-function analysis of pro-apoptotic factors
suggests that Bim and PUMA play significant roles in p53-mediated developmental
blockade, while Bax and Noxa do not, despite the very large induction in Noxa expression.
PUMA/p21waf double-deficiency fails to cooperate in alleviating developmental block of
Rpl22−/− T cell progenitors
Our analysis of the roles of pro-apoptotic effectors revealed that the combined elimination of
Bim and PUMA resulted in nearly complete rescue of development, suggesting that
simultaneous elimination of other p53 effectors might be informative. Since p53 regulates
both cell cycle through p21waf and apoptosis through PUMA and Bim, we asked how
simultaneously disabling p53’s ability to mediate cell cycle arrest (p21waf-deficiency) and
promote apoptosis (PUMA-deficiency) would affect development of Rpl22-deficient
progenitors. That is, we asked whether Rpl22/PUMA/p21waf triple-deficiency would more
completely rescue development. Surprisingly, we observed that p21waf-deficiency
eliminated even the partial rescue in development of Rpl22−/− thymocytes afforded by
PUMA deletion alone (Figure 8A). Both total thymic cellularity as well as the proportion
and absolute numbers of DP thymocytes were decreased to levels exhibited by mice singly
deficient in Rpl22 (Figure 8A). DN subpopulations were not significantly altered, as
expected since they remained unchanged even in Rpl22/PUMA-deficient mice (Figure 8B).
Evaluation of bromodeoxyuracil (BrdU) incorporation as a means of measuring the number
of cells in S phase, revealed that despite their increased expression of p21waf, Rpl22−/− DN3
thymocytes actually incorporated more BrdU than Rpl22+/+ littermate controls (Figure 8C).
Therefore, for reasons that are unclear, Rpl22-deficiency appears to increase the
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proliferation of DN3 progenitor cells. It is possible that the increased proliferation of these
cells may them more sensitive to p53-induced apoptosis. Consistent with this notion, while
we detected only modest changes in the extent of BrdU incorporation between Rpl22/
PUMA-double deficient and Rpl22/PUMA/p21waf-triple deficient thymocytes (DN4; Figure
8C), triple-deficient thymocytes did exhibit greater levels of apoptosis than did thymocytes
from Rpl22/PUMA-double deficient mice in many of the subsets analyzed (Figure 8D).
These surprising findings suggest that p21waf was actually functioning to facilitate
development in the Rpl22/PUMA-double deficient mice, either through subtly restraining
proliferation or by promoting survival, since the additional loss of p21waf resulted in
increased cell death.
These data indicate that the p53-mediated developmental block in Rpl22-deficient
thymocytes results from the coordinate induction of a constellation of p53 targets, with the
pro-apoptotic factors PUMA and Bim, playing predominant roles in enforcing the p53-
mediated developmental arrest. Collectively, these p53 effectors are limiting proliferation
and survival in a manner distinct from that observed following induction of p53 through
other means, such as DNA damage.
Discussion
Rpl22-deficient thymocytes fail to progress beyond the β-selection checkpoint due to the
activation of a p53-mediated checkpoint. The importance of this checkpoint in mediating the
developmental block is demonstrated by the complete restoration of T cell development
upon ablation of Trp53 in Rpl22−/− thymocytes (Figure 1). Herein we analyzed the
downstream p53 effectors responsible for the p53-mediated developmental arrest of
Rpl22−/− αβ-lineage precursors. Expression profiling revealed that while many p53 effectors
capable of regulating cell growth and survival were induced, few played sufficiently
important roles as to alleviate (partially) the developmental block upon removal. Indeed, we
found that the expression of a cell cycle inhibitor, p21waf, as well as the pro-apoptotic
factors PUMA, Bim, Bax, and Noxa were all induced in Rpl22−/− thymocytes. Nevertheless,
only elimination of PUMA and Bim resulted in detectable restoration of T cell development,
with nearly full restoration of development occurring upon simultaneous elimination of
both. Therefore, our results indicate that even within the same tissue, different inductive
stimuli (e.g., DNA damage vs. RpL22 deficiency) result in the utilization by p53 of a
somewhat distinct set of molecular effectors to limit cell growth and survival.
Our loss-of-function analysis of p53 effectors revealed that elimination of individual p53
molecular effectors had limited ability to alleviate the p53-mediated block and restore
development. While not a direct target of p53, Bim expression was elevated in Rpl22−/−
DN3 thymocytes. The ability of Bim knockdown to partially restore development of
Rpl22−/− thymocytes beyond the β-selection checkpoint to the DP stage is consistent with a
report indicating that Bim is an important death effector at this checkpoint, in that Bim
deficiency was able to partially restore development of pre-TCR–deficient thymocytes (42).
Furthermore, we observed that combined reductions in Bim and PUMA resulted in nearly
complete rescue of the development of Rpl22−/− T cell progenitors in vitro. The results are
in agreement with recent findings that indicate combined Bim, PUMA, and Bid loss
prevents direct activation of Bax/Bak-mediated apoptosis (43). Likewise, the failure of Noxa
and Bax knockdown to restore development or Rpl22−/− thymocytes is consistent with
previously published analyses (44). Noxa is reported to induce apoptosis indirectly by
promoting Bax and Bak function and to require oncogene expression (e.g., oncogene E1A)
for maximal effect (23). Moreover, because Noxa was also upregulated in Rpl22−/− γδ-
lineage cells, which do not show p53 induction or arrested development, we reasoned that
Noxa induction might be p53-independent and therefore unlikely to play a major role in the
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p53-mediated developmental block at the β-selection checkpoint. Lastly, knockdown of the
Bcl-2 family member, Bax, also failed to rescue development, perhaps because the pro-
apoptotic function of Bax is reported to be less potent in thymocytes than that of Bim (45),
and because Bax deficiency is reported to produce a mild rescue of development block
caused by the absence of IL-7 signaling, but is not known to play a major role at the β-
selection checkpoint (46). Alternatively, the related pro-apoptotic protein Bak can also form
homodimers that result in mitochondrial disruption and cytochrome c efflux, and thus might
compensate for Bax loss (47).
It was quite surprising that ablation of the two major p53 effectors controlling cell growth
and survival in the thymus, p21waf and PUMA, respectively, not only failed to rescue
development completely but also behaved antagonistically when eliminated simultaneously.
Indeed, PUMA-deficiency is able to render thymocytes completely resistant to p53-mediated
death following exposure to DNA damage (21); however, PUMA-deficiency failed to fully
rescue the development of Rpl22−/− thymocytes, instead restoring thymic cellularity to only
~10% of normal levels. While co-elimination of Bim and PUMA was able to provide nearly
complete rescue of the development of Rpl22−/− thymocytes in vitro, presumably due to a
complete suppression of p53-mediated apoptosis, co-elimiation of PUMA with cell cycle
regulator p21waf not only failed to alleviate the developmental block of Rpl22−/−
thymocytes but also rendered the developmental block more penetrant, interfering with the
ability of PUMA-deficiency to restore development to the DP stage (Figure 8). The
mechanistic basis by which p21waf deficiency antagonizes the rescue of development by
PUMA-deficiency remains unclear as we detected only modest changes in BrdU
incorporation caused by further elimination of p21waf (Figure 8C). Nevertheless, it is
possible that even subtle changes in proliferation could be biologically relevant, as cells in
cycle have been reported to be more sensitive to p53-mediated apoptosis and PUMA-
deficiency may be unable to rescue cells from p53-mediated death in this context (48, 49).
Consistent with this possibility, 21waf-deficiency did result in increased apoptosis in many
thymocyte subsets from Rpl22/PUMA/p21waf-deficient mice. This outcome may be a
consequence of the aforementioned subtle effects on proliferation. Alternatively, recent
studies have demonstrated an anti-apoptotic role for p21waf under certain cell stress
conditions (50–53). The greater sensitivity of proliferating cells to cell death may also play
an important role in rendering αβ lineage cells more sensitive to developmental block in
Rpl22–/– mice (7). Indeed, we also made the surprising observation that despite expressing
higher levels of p21waf, Rpl22−/− thymocytes incorporated more BrdU than their wild type
littermates. The mechanistic basis for this is unclear but is under active investigation.
Moreover, αβ lineage progenitors are thought to undergo much more extensive proliferation
than do γδ lineage progenitors (54, 55) and this may contribute to their increased sensitivity
to development arrest due upon loss of Rpl22.
The cause of p53 induction in Rpl22−/− thymocytes remains unclear, but we have shown
that it is associated with increased p53 synthesis, not a change in turnover (7). Because we
observe p53 induction in Rpl22−/−Rag2−/− thymocytes, it does not result from the Rag2-
mediated DNA cleavage events associated with TCR gene rearrangements. Moreover, the
absence of a change in p53 stability suggests it is not due to other forms of DNA damage,
consistent with the incomplete dependence of the resulting cell death on PUMA (21).
Instead, our current hypothesis is that induction of p53 in Rpl22−/− αβ lineage cells results
from stress that is a consequence of the proliferative burst accompanying pre-TCR
stimulation at the DN3 stage. This idea is consistent with the developmental block in
Rpl22−/− thymocytes being selective to those of the αβ lineage, since these cells undergo a
robust proliferative expansion following pre-TCR signaling, than does not occur during
development of γδ lineage progenitors (54, 55). In agreement, we observed a transient
induction of p53 following acute, mitogenic anti-CD3 stimulation of Rpl22-expressing
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Rag2−/− thymocytes, which mimics pre-TCR stimulation (7) (Figure 3). We think the reason
that p53 induction is normally transient is because pre-TCR signaling induces Rpl22
expression, which then returns p53 levels to baseline by repressing p53 synthesis. We
hypothesize that p53 induction is sustained in Rpl22−/− αβ lineage cells, because Rpl22 is
not present and so is incapable of repressing p53 translation. Nevertheless, it is possible that
there are normal circumstances where p53 induction might be sustained, such as when the
Notch signals upon which development of αβ lineage cells depend are unavailable. Indeed,
since Notch signaling has been reported to repress p53 (and induce Rpl22)(56, 57), it is
tempting to speculate that the absence of Notch signals could selectively eliminate αβ
lineage cells through sustained p53-induction, since γδTCR+ thymocytes develop in a
Notch-independent manner (58).
Our findings reveal that p53 induction in Rpl22−/− αβ lineage thymocytes impairs their
development through multiple molecular effectors controlling growth and survival. The
particular effectors employed appear to differ depending on the circumstances surrounding
p53 activation. Indeed, while the p53 effector Noxa functions in the context of oncogene
induction, PUMA is almost solely responsible for p53-mediated death following DNA-
damage. In contrast, multiple direct and indirect p53 effectors (PUMA, miR-34a, Bim and
perhaps others) are employed to impair development of Rpl22−/− thymocytes. Efforts to
address the basis for the selective induction of p53 in Rpl22−/− αβ lineage cells and how this
influences the constellation of effector molecules controlling growth and survival are in
progress.
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Figure 1.
Trp53 deletion restores development to Rpl22-deficient mice. (A) Single cell suspensions of
thymocytes from mice with the indicated genotypes are shown. FACS plots show CD4 and
CD8 expression on thymocytes that were gated on doublet excluded, live lymphocytes. Cell
numbers were calculated by multiplying the absolute cell number of the thymus by the
fraction of each indicated subset identified by FACS analysis. Bar graphs show the mean of
the absolute cell number ± s.d. (B) Gated DN thymocytes from mice used in (A) were
stained with anti-CD25 and CD44 to reveal DN fractions. Bar graphs show the mean of the
absolute cell numbers ± s.d. for the indicated subsets (C) Annexin V binding and PI staining
on total thymocytes. Bar graphs show the mean of the fold increase in apoptosis ± s.d.
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within each subset as compared to Rpl22-sufficient T cells. N=5 mice per genotype, per
analysis. Results are representative of at least 3 independent experiments. *P-value <0.05,
**P-value <0.01,***P-value < 0.001.
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Figure 2.
Quantitative real-time PCR analysis of mRNA encoding p53 targets in αβ- or γδ-lineage
thymocytes. Thymocytes were pooled from 12 Rpl22+/+, 13 Rpl22−/−, or 6 Rpl22+/− mice,
and the indicated populations were isolated by flow cytometry and used to generate cDNA:
DN3 (γδTCR−CD4−CD8−CD44−CD25+) or γδ lineage (CD4−CD8−γδTCR+). Analysis for
each primer/probe set was performed for each cell type in triplicate. mRNA levels were
normalized to GAPDH. Bar graphs show the fold change (2−ΔΔCt or RQ value + RQ max)
over Rpl22+/+ DN3 cells. Results are representative of two independent experiments. P
values were calculated for triplicate measurements within each experiment. **P-value
<0.01, ***P-value <0.001.
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Figure 3.
Analysis of p53 targets following acute mitogenic stimulation of Rpl22−/–Rag2−/− T cell
precursors. (A) FACS plots of pooled thymocytes isolated from mice 24 hr after
intraperitoneal injection with PBS (control) or anti-CD3 mAb. FACS plots show staining for
CD44, CD25, or CD5 within DN (CD4−CD8−) subsets from Rag2−/− mice of the indicated
genotypes. (B) Detergent extracts of thymocytes isolated from Rpl22+/+Rag2−/− or
Rpl2−/−Rag2−/− mice stimulated for the indicated times as in (A) were immunoblotted with
anti-p53, RpL22, or GAPDH antibodies. (C) Quantitative real-time PCR analysis of DN
thymocytes from mice injected with PBS or anti-CD3 as in (A). Live, DN thymocytes were
isolated by flow cytometric-based cell sorting and used to generated cDNA. mRNA levels
were normalized to GAPDH. Bar graph indicates fold change (2−ΔΔCt or RQ) over control
treated Rpl22+/+Rag2−/− (plus RQ max). Results are representative of 3 independent
experiments. P values were calculated for triplicate measurements within each experiment.
*P-value < 0.05; **P-value < 0.01; ***P-value < 0.001.
Stadanlick et al. Page 18
J Immunol. Author manuscript; available in PMC 2012 July 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4.
Enforced expression of miR-34a arrests thymocyte development. (A) Quantitative real-time
PCR analysis of miR-34a expression 24 h after intraperitoneal injection of Rag2−/− mice of
the indicated genotypes with either PBS or anti-CD3. Graphs show mean ± s.d. of the fold
increase of mir-34a expression (normalized to small RNA sno-202) from triplicate wells
over PBS treated Rpl22+/+ DN cells. Results representative of 3 independent experiments.
(B–C) Effect of enforced expression of mir-34a on development of thymocytes to the DP
stage. DN thymocytes were transduced with miR-34a (pMiY-MIR34) as well as empty
vector (pMiY) and mutated mir-34a (pMiY-MIR34M) controls and cultured on OP9-DL1
expressing monolayers. Histograms of gated GFP+ cells are depicted in (B). The absolute
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number of transduced (GFP+) DP thymocytes was determined by flow cytometry at the
indicated time post transduction and the mean ± s.d. of triplicate wells represented
graphically in (C). Results are representative of three independent experiments. P values
were calculated for triplicate measurements within each experiment.***p-value<0.001.
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Figure 5.
p21waf deficiency does not restore development to Rpl22-deficient T cells. (A) Histograms
depict single cell suspensions of thymocytes from mice with the indicated genotypes stained
and gated as in Figure 1. Bar graphs show the mean absolute cell numbers ± s.d. for the
indicated thymocyte subsets. (B) FACS analysis of DN subsets from mice in (A). Bar graphs
show mean absolute cell number ± s.d. for each DN subset. (C) Total Annexin V and PI
staining of thymocytes from (A). The increase in apoptosis is represented graphically
showing mean of the fold increase in apoptosis over Rpl22-sufficient thymocytes ± s.d. for
each subset. N=5 or more mice from each genotype for each analysis. Results representative
of 3 independent experiments.
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Figure 6.
PUMA-deficiency partially relieves the block in T cell development in Rpl22-deficient
mice. Single cell suspensions of thymocytes from mice with the indicated genotypes were
subjected to FACS analysis as described in Figure 1. (A) CD4 and CD8 expression on
thymocytes from indicated mice. Bar graphs show the mean absolute cell number ± s.d. for
each thymocyte subset. (B) Analysis of gated DN subsets from mice with indicated
genotypes. Bar graphs show absolute number ± s.d. (C) FACS plots showing Annexin V and
PI staining of total thymocytes. Graphs represent the mean of the fold increase in apoptosis
over Rpl22+/+ mice for each thymocyte subset. Results representative of 3 independent
experiments. ***p-value<0.001.
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Figure 7.
Co-elimination of Bim and PUMA restores development of αβ lineage RpL22-deficient
thymocytes. (A) Effect of single-knockdown of p53 effectors on devopment of Rpl22−/−
progenitors. Fetal liver progenitors were retrovirally transduced with shRNAs targeting the
indicated genes and were cultured on OP9-DL1-bearing monolayers. Developmental
progression was assessed by FACS analysis with the indicated antibodies at day 12 post-
transduction. Histograms represent gated, GFP+ transduced cells. (B) Fetal liver progenitors
from Rpl22−/−Puma+/+ or Rpl22−/−Puma−/− mice were transduced with the indicated
shRNAs and treated as in (A). Results are representative of 3 independent experiments
performed in triplicate wells. (C) Bar graph showing percent of maximum rescue, defined as
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the proportion of Rpl22−/−Puma+/+ cells reaching the DP stage upon p53 knockdown. Bar
graph shows mean ± s.d. of the percent max on day 12 post transduction for cells transduced
with control (Cntrl), Bim, Noxa, or Bax shRNA. Statistical student’s t-tests is a comparison
to Rpl22−/−Puma+/+ control shRNA group; *p-value < 0.05, ***p-value < 0.001. (D)
Immunoblots verify the extent of target knockdown in Scid.adh thymic lymphoma cells by
the shRNAs utilized. Knockdown of Noxa was assessed by co-expressing the Noxa shRNA
with a myc-tagged Noxa construct and blotting for the anti-Myc-Tag.
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Figure 8.
p21waf deficiency abrogated the rescue of development caused by PUMA-deficiency alone.
Single cell suspensions of thymocytes from mice with the indicated genotypes were
subjected to FACS analysis. (A) CD4 and CD8 expression on thymocytes. Bar graphs show
the mean absolute cell number ± s.d. for each thymocyte. (B) Analysis of DN subsets from
mice with indicated genotypes. Bar graphs show absolute number ± s.d. (C) BrdU and 7-
AAD staining of DN3 gated thymocytes from wildtype (wt), Rpl22-deficient, Rpl22/
PUMA-double deficient or Rpl22/Puma/p21waf triple deficient mice. Bar graphs show the
mean of the percentage of BrdU+ 7-AAD− cells in DN, DN3, and DN4 subsets ± s.d. N=3 to
5 mice from each genotype from 3-independent experiments. (D) FACS plots showing
Annexin V and PI staining of total thymocytes. Graphs represent the mean of the fold
increase in apoptosis over RpL22+/+ mice for each T cell subset. *p-value >0.5, **p-value
>0.01, ***p-value >0.001.
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